Treatment-associated decline in JAK2V617F allele burden in polycythemia vera: What does it mean?

被引：2
|
作者：
Tefferi, Ayalew [1 ]
Pardanani, Animesh [1 ]
Gangat, Naseema [1 ]
机构：
[1] Mayo Clin, Dept Med, Div Hematol, 200 First St SW, Rochester, MN 55905 USA
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2024年 / 99卷 / 08期
关键词：
HYDROXYUREA; MUTATIONS; THERAPY; CALRETICULIN; RUXOLITINIB; JAK2(V617F); TRIAL; AGE;
D O I：
10.1002/ajh.27375
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1459 / 1461
页数：3
相关论文
共 50 条
  • [31] Effect of busulfan on JAK2V617F allele burden
    Randi, Maria Luigia
    Santarossa, Claudia
    Peroni, Edoardo
    Cosi, Elisabetta
    Duner, Elena
    Bertozzi, Irene
    Fabris, Fabrizio
    HAEMATOLOGICA, 2014, 99 (03) : E44 - E44
  • [32] Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia
    Richsten, Anne
    Palmqvist, Lars
    Johansson, Peter
    Andreasson, Bjoern
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 (08): : 1260 - 1261
  • [33] EXPRESSION OF HETEROZYGOUS OR HOMOZYGOUS JAK2V617F IN PATIENTS WITH POLYCYTHEMIA VERA
    Cacciola, R.
    Di Francesco, E.
    Ferlito, C.
    Pezzella, F.
    Seria, E.
    Cacciola, E.
    EXPERIMENTAL HEMATOLOGY, 2011, 39 (08) : S58 - S58
  • [34] JAK2V617F Impairs T Cell Differentiation in Polycythemia Vera
    Choi, Daniel C.
    Abu-Zeinah, Ghaith
    Di Giandomenico, Silvana
    Erdos, Katie
    Scandura, Joseph
    BLOOD, 2022, 140 : 6746 - 6747
  • [35] Mutational analysis of JAK2V617F in tunisian polycythemia vera patients
    Frikha, R.
    Elloumi, M.
    Kamoun, H.
    CLINICA CHIMICA ACTA, 2024, 558
  • [36] Dynamic Increase in JAK2V617F Allele Burden Is a Predictive Parameter for the Transformation into Myelofibrosis from Polycythemia Vera and Essential Thrombocytosis
    Shirane, Shuichi
    Araki, Marito
    Morishita, Soji
    Hironaka, Yumi
    Noguchi, Masaaki
    Koike, Michiaki
    Hirano, Takao
    Ohsaka, Akimichi
    Komatsu, Norio
    BLOOD, 2014, 124 (21)
  • [37] JAK2V617F allele burden in patients with myeloproliferative neoplasms
    Salem H. Alshemmari
    Reshmi Rajaan
    Reem Ameen
    Mohammad A. Al-Drees
    Marwa R. Almosailleakh
    Annals of Hematology, 2014, 93 : 791 - 796
  • [38] JAK2V617F allele burden in patients with myeloproliferative neoplasms
    Alshemmari, Salem H.
    Rajaan, Reshmi
    Ameen, Reem
    Al-Drees, Mohammad A.
    Almosailleakh, Marwa R.
    ANNALS OF HEMATOLOGY, 2014, 93 (05) : 791 - 796
  • [39] Engineering a humanized animal model of polycythemia vera with minimal JAK2V617F mutant allelic burden
    Parsons, Tyler M.
    Krishnan, Aishwarya
    Dunuwille, Wangisa M. B.
    Young, Andrew L.
    Arand, Jason
    Han, Wentao
    Challen, Grant A.
    HAEMATOLOGICA, 2024, 109 (03) : 968 - 973
  • [40] RUXOLITINIB (RUX) REDUCES JAK2V617F ALLELE BURDEN (AB) IN PATIENTS (PTS) WITH POLYCYTHEMIA VERA (PV) ENROLLED IN THE RESPONSE STUDY
    Vannucchi, A. M.
    Verstovsek, S.
    Guglielmelli, P.
    Griesshammer, M.
    Burn, T. C.
    Naim, A.
    Paranagama, D.
    Marker, M.
    Tiecke, E.
    Gadbaw, B.
    Kiladjian, J. J.
    HAEMATOLOGICA, 2016, 101 : 163 - 164
12345